| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 9
| Issue : 1 | Page : 11-14 |
|
|
Surgical management of male breast cancer patients referred to the national cancer institute: University of Gezira; the forgotten lesson
Ahmed M Elhaj1, Ahmed A Alshaikh2, Dafalla O Abuidris1, Algaylani A Eltayeb1
1 Department of Oncology, National Cancer Institute University of Gezira, Wad Madani, Sudan
2 Department of Surgery, Faculty of Medicine, University of Gezira, Wad Madani, Sudan
Correspondence Address:
Ahmed M Elhaj
National Cancer Institute, University of Gezira, Wad Madani, PO Box 20
Sudan
  | Check |
DOI: 10.4103/1858-5000.144646 
|
|
|
Background: Male breast cancer (MBC) is a rare disease accounting for about 1% of breast cancer patients worldwide. There is a lack of data about MBC patients and their management in Sudan. Patients and Methods: Medical records of all cancer patients treated at the Department of Oncology, National Cancer Institute-University of Gezira (NCI-UG), Wad Medani, Gezira State, Sudan, in the period from April 1999 to December 2010, were reviewed with regard to MBC. Variables assessed were individual, clinical characteristics, and initial surgical treatment. Results: There were 1,505 (19.2%, 1505/7836) Sudanese breast cancer patients treated at the NCI-UG from April 1999 to December 2010. The MBC frequency was 2.3% (34/1505); all were included in the current study. Eighteen patients underwent upfront surgery and these patients formed the subjects for the current study. Mastectomy and axillary clearance (AC) was performed for 11 (32.4%) patients. The rest- 7 patients- underwent total mastectomy only. The incidence of positive surgical margins is remarkable (27%). Only one of those with positive surgical margin was subjected to re-excision. Among those who underwent AC only two had adequate axillary lymph nodes clearance. Discussion: The results have been compared with similar studies and showed similar approach in management with minor differences Conclusion: These results indicated inadequate surgical management and urgent needs for improvement in the treatment of this rare type of cancer. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
